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     Polycystic ovary syndrome (PCOS) is a common endocrine / metabolic disorder in women of 
reproductive age .Abdominal adiposity and obesity are frequently present in PCOS. It now appears that, 
obesity is associated with a low-grade inflammation of white adipose tissue. 
Adipokines play a significant role in the pathogenesis of a low-grade inflammation associated with 
obesity. Among variety of adipokines, resistin and visfatin are proposed as important pro inflammatory 
mediators and they have recently been suggested to be associated with obesity related diseases. 
The aim of this study is to evaluate the correlation of visfatin and resistin serum levels and the ratio of 
these two adipokines with BMI in PCOS women under age of 35 years old. Twenty eight young women 
with clinically confirmed PCOS disease (14 lean and 14 obese), and 12 young, healthy and lean women 
with stable weight and BMI<25 were enrolled. Blood was obtained from the included persons, and 
visfatin and resistin were assessed by ELISA method. We did not observe any significant differences in 
serum visfatin and resistin concentrations and also in the Visfatin/Resistin ratio between PCOS and 
control group. Also we did not found a significant correlation between visfatin and resistin with BMI. 
This study demonstrated that serum resistin and visfatin levels do not seem to be directly involved in the 
pathology of PCOS. 
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INTRODUCTION 
      Polycystic ovary syndrome (PCOS) is one 
of the most common endocrine disorders in 
premenopausal women with 6–7% 
prevalence’s worldwide [1–3]. PCOS should 
be considered a life span disorder. Aside from 
the cutaneous and reproductive manifestations 
that appear peripubertally, this disorder is 
frequently associated with obesity [4], insulin 
resistance and type 2 diabetes [5,6], low-grade 
chronic inflammation [7], oxidative stress [8], 
and increased in cardiovascular risk [9, 10]. 
Currently PCOS is considered a complex 
multigenic disorder, in which multiple genetic, 
epigenetic, and environmental factors play a 
significant role in the development of the 
hyperandrogenic, reproductive, and metabolic 
phenotype of the syndrome [7]. Substantial 
evidence indicates that obesity plays a pivotal 
role in the pathogenesis of PCOS. In obesity 
mouse models, severe macrophage invasion was 
observed in the vascular⁄stromal compartment 
of adipose tissue, suggesting that excess 
adiposity is associated with chronic 
inflammation [11, 12]. In patients with PCOS, 
dysfunction of adipose tissue has been observed 
with the over-production of some pro-
inflammatory adipokines. Resistin and visfatin 
are cytokines that secreted by visceral adipose 
tissue, and recently suggested that these 
cytokines are associated with obesity related 
diseases [13, 14]. The expression of human 
resistin is predominantly localized in 
macrophages and stroma cells in adipose tissue 
 




rather than adipocytes [15, 16]. As a secreted 
circulating protein, resistin can exert its 
functions in both endocrine and paracrine 
manners [16]. 
 In human studies, resistin circulating levels or 
gene expression have varied from increased to 
unchanged in obesity, PCOS or type 2 diabetes 
mellitus [17-24]. Visfatin, an adipokine isolated 
by Fukuhara et al. [25], corresponds to a protein 
identified previously as pre-B cell colony-
enhancing factor (PBEF), a 52 kDa cytokine 
expressed and secreted by lymphocytes [26]. 
Visfatin appears to be an important mediator of 
inflammation [27]. There are also conflicting 
data on visfatin circulating levels in obese 
humans. Some studies showed the increased 
levels of visfatin [28, 29], but there are studies 
that didn’t confirm this [30]. The status of the 
circulating levels and gene expression of these 
cytokines in PCOS is also controversial [31, 
32]. 
The aim of this study was to evaluate the serum 
levels of visfatin and resistin in PCOS patients 
under the age of 35 years old and highlighting 
the probable correlation of them with BMI. 
 
MATERIALS AND METHODS 
Subjects 
      A group of 28 women with PCOS (14 
normal weight and 14 obese) based on NIH 
diagnostic criteria were evaluated. The clinical 
criteria included oligomenorrhoea or 
amenorrhoea dating from menarche. The 
biochemical criteria were increased LH 
concentration, LH/FSH (luteinizing 
hormone/follicle stimulating hormone) ≥2~3, 
and elevated T (testosterone) levels. Clinical 
hyperandrogenism was quantified by the 
modified Ferriman–Gallwey score and 
hirsutism was defined when the score was ≥8. 
Normal weight was defined as body mass index 
from 18.5 to 24.9 kg/m
2
 and obesity as BMI ≥ 
25.0 kg/m
2
. The women with PCOS were under 
35 years old (mean±SD of age =28.21±3.61). 
Twelve healthy women with age<35 (mean±SD 
of age = 26.91±3.31) years and BMI<25 
(mean= 22.67±1.52) were enrolled as the 
control group. Since this study was aimed at 
exploring further the contribution of obesity, 
only lean subjects were included in control 
group and the data analysis. Subjects who were 
obese (BMI>25) were excluded. 
The controls had a regular menstrual cycle and 
no chronic or acute disease. In our study, 
participants with Cushing’s syndrome, thyroid 
dysfunction, androgen-secreting tumor, and 
enzyme deficiency (21-hydroxylase in 
particular) were excluded. The patients were not 
undergoing pharmacological treatment. Other 
exclusion criteria included smoking and alcohol 
abuse. In all subjects anthropometric 
measurements (body mass and height) were 
determined, and body mass index (BMI) was 
calculated according to the standard formula. 
The study was conducted after obtaining 
informed consent from each participant and 
approved by the Ethical Committee of Shahid 
Beheshti University of Medical Sciences. All of 
the women were studied between days 3 and 6 
of the menstrual cycle. Blood samples were 
taken from the participants between 7:00 AM 
and 9:00 AM in the morning while sitting, using 
vacutainer tubes after a 12-hour overnight fast. 
Samples were centrifuged within 30 to 45 
minutes of collection and stored at -80°C. 
Laboratory procedures 
     Visfatin (CSB-E08940h) and resistin (CSB-
E06884h) were measured by a sandwich 
enzyme-linked immunosorbent assay (ELISA) 
method and using materials provided by 
Cusabio Inc.  
The lower detectable concentrations were 0.156 
(ng/ml) for visfatin and 0.078 (ng/ml) for 
resistin. The respective inter- and intra-assay 
coefficients of variation were <10% and <8% 
for both visfatin and resistin according to the 
manufacturer claims. 
Statistical analysis 
      Statistical analyses were performed using 
16.0 PC package (SPSS Inc., Chicago, IL). The 
Kolmogorov-Smirnov test was applied to both 
groups to test the normal distribution for each 
variable. Only resistin had non-normal 
distribution. Anthropometric data and hormonal 
values were presented as mean±SD. The 
Kruskal-Wallis Test was used for subgroups 
comparisons of mean serum resisitin levels and 
the Visfatin / Resistin ratio. Mean values of 
serum visfatin were compared with the analysis 
of variance (ANOVA) test. Univariate 
correlation coefficients were calculated 
according to Spearman rank-order equation for 
relationship between resistin and Visfatin / 
Resistin ratio with BMI, and Pearson’s 
correlation coefficient for relationship between 
visfatin and BMI. We considered p<0.05 as 
statistically significant.  
 
 





   The clinical characteristics of the studied 
groups are shown in Table 1. 
Patients with PCOS and controls were in similar 
age. There was no difference in BMI between 
normal weight PCOS subgroup and controls. As 
expected, BMI were significantly higher in the 
obese PCOS subgroup than in the normal 
weight PCOS subgroup and the controls. 
The hormonal characteristics of the studied 
groups are shown in Table 2. 
Mean serum of resistin was higher in women 
with PCOS in both subgroups than the controls, 
whereas no statistically significant difference 
existed between them. But there was a 
significant difference in mean resistin levels 
between all PCOS and the controls (p=0.46). 
We did not observe any significant differences 
in mean serum visfatin concentrations and the 
Visfatin / Resistin ratio between PCOS 
subgroups and in comparison to the control 
group. 
   We did not found any Correlations between 
serum resistin and visfatin levels with BMI. 
And also no correlation between visfatin/resistin 
ratio and BMI has been observed (Table 3).
Table 1. Clinical characteristics of the studied groups  
* p < 0.001 obese PCOS vs. controls. 
 
Table 2. Hormonal characteristics of the studied groups  
* p < 0.05 all PCOS vs. control. 
^ Ratio (V/R); visfatin / resistin of each individuals 
 







     The results of our study showed no 
significant difference in resistin serum levels 
between groups, which is supported by several 
other studies [23, 33-36]. 
Seow et al. was reported that resistin mRNA 
levels were twofold higher in adipocytes from 
PCOS than in those from normal controls [21]. 
These results may indicate that resistin may 
have a local paracrine action in adipose tissue of 
PCOS patients. As in humans, resistin is 
predominantly expressed in macrophages and 
adipocyte precursor cells in visceral fat [37, 38]. 
Although we did not observe any correlation 
between serum resistin levels and BMI, Xita et 
al. were showed that the resistin gene 
polymorphism is associated with BMI in 
women with PCOS. These findings suggesting 
that resistin might be related to adiposity in a 
different regulatory mechanism in PCOS (39). 
In the present research we did not find a 
difference in serum visfatin levels between 
patients with PCOS in both subgroups and the 
control group.  
And also several recently published studies also 
did not find a difference in plasma or serum 
visfatin levels between patients with PCOS and 
the control group [40-42].  
Zwirska-Korczala et al also did not detect a 
difference in visfatin levels between lean PCOS 
subjects and lean controls [43]. 
Lajunen et al. found no association between 
circulating full-length visfatin levels and PCOS, 
obesity or metabolic markers, and suggested 
that visfatin may act as a pro-inflammatory 
cytokine [41].  
Clinical 
characteristics 
All PCOS Lean PCOS Obese PCOS Controls 
N 28 14 14 12 
Age (years) 28.21±3.61 26.92±3.64 29.50±3.20 26.91±3.31 
BMI (kg/m
2
) 25.56±3.58 22.72±1.40 28.39±2.71* 22.67±1.52 
Hormonal characteristics All PCOS Lean PCOS Obese PCOS Controls 
N 28 14 14 12 
MEAN Resistin (ng/ml) 2.08±2.80* 1.98±3.14 2.19±2.53 0.74±0.54 
MEAN Visfatin (ng/ml) 3.24±0.99 3.29±0.89 3.19±1.12 3.28±0.82 
Ratio (V/R)^ 4.77±6.97 3.95±2.92 5.59±9.54 9.04±10.20 
Correlation Resistin Visfatin Ratio (V/R)
 
BMI 
Lean PCOS 0.14 0.91 0.21 
Obese PCOS 0.14 .076 0.18 
Controls 0.77 0.24 0.44 
 




As many studies also demonstrated that 
visfatin displayed pro-inflammatory 
properties and modulated immune functions 
[27, 44]. Our results showed no correlation 
between serum visfatin and BMI, which is 
also reported in Lajunen’s et al. study [41]. 
But the others demonstrated higher serum 
visfatin levels in lean PCOS subjects than 
the lean controls and the correlation of this 
hormone with BMI [45-48]. The Seow’s et al 
study indicated that PCOS is associated with 
increased visfatin mRNA concentrations in 
PBMCs and in omental adipose tissue. 
However, only visfatin mRNA concentration 
in omental adipose tissue is closely 
correlated with BMI [49].thus these result 
may indicate that serum visfatin may not 




      This study demonstrated that serum 
resistin and visfatin levels do not seem to be 
directly involved in the pathology of PCOS . 
It is possible that these hormones might act 
with their pro-inflammatory characteristics 
as local determining factor in adipose tissue 
that is not reflected in patient’s serum. 
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